Singhi 2003.

Methods	Randomized controlled trial Duration: recruitment from June 1999 to June 2000. Participants were followed up for 12 months.
Participants	Number: 147 randomized, 122 included in the analysis (68 male, 54 female) Inclusion criteria: children with seizures for less than 3 months and up to 3 small enhancing lesions in parenchyma Exclusion criteria: raised intracranial pressure, focal neurological deficit, neurodevelopmental delay, any chronic systemic disease, other lesions on imaging, evidence of tuberculosis Type of lesion: non‐viable
Interventions	Group 1. Oral prednisolone: 2 mg per kg once daily for 5 days plus 15 mg per kg per day albendazole for 4 weeks starting 2 days after prednisolone started Group 2. Oral prednisolone: 2 mg per kg once daily for 5 days plus 15 mg per kg per day albendazole for 1 week starting 2 days after prednisolone started
Outcomes	Included in the review: persistence of lesions at 1 month; recurrence of seizures within 12 months; epigastric discomfort with treatment Not included in the review: lesion size reduced at 6 months
Notes	Location: India Source of funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Quote: "...they were randomized according to random number tables..." Decision: done
Allocation concealment?	Unclear risk	Not described Decision: unclear
Blinding? All outcomes	Low risk	Quote: "None of the persons involved in the study (i.e. patient, investigators and neuroradiologist) was aware of this random allocation. The code was opened only after completion of the study" Decision: done
Incomplete outcome data addressed? All outcomes	High risk	147 randomized, 25 excluded due to poor compliance with treatment or inadequate follow up (83% included in the analysis). No discussion of the differences between participants included in the analysis and those excluded.
Free of selective reporting?	Low risk	No evidence of selective reporting
Free of other bias?	Low risk	No evidence of other bias